The Forward trial enrolls promising patients with chronic neutropenia, aligning well with the commercial market demand. The patient profile targets 50,000 diagnosed CN patients in the US, aiming for a broad label to cover the entire CN population.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing